| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thalamus | 53 | 2020 | 136 | 11.330 |
Why?
|
| Geniculate Bodies | 108 | 2019 | 138 | 8.580 |
Why?
|
| Cerebral Cortex | 29 | 2021 | 574 | 5.460 |
Why?
|
| Smoking Cessation | 22 | 2023 | 310 | 5.160 |
Why?
|
| Neural Pathways | 44 | 2020 | 334 | 4.860 |
Why?
|
| Somatosensory Cortex | 19 | 2019 | 113 | 4.810 |
Why?
|
| Neurons | 68 | 2019 | 1634 | 4.330 |
Why?
|
| Substance Abuse, Intravenous | 10 | 2025 | 76 | 4.210 |
Why?
|
| Thalamic Nuclei | 18 | 2017 | 32 | 3.820 |
Why?
|
| Auditory Cortex | 13 | 2018 | 63 | 3.780 |
Why?
|
| Synapses | 34 | 2018 | 281 | 3.650 |
Why?
|
| Receptors, Metabotropic Glutamate | 17 | 2015 | 50 | 3.560 |
Why?
|
| Visual Cortex | 40 | 2018 | 245 | 2.880 |
Why?
|
| Veterans | 15 | 2025 | 120 | 2.860 |
Why?
|
| Cats | 104 | 2007 | 283 | 2.780 |
Why?
|
| Thyroid Neoplasms | 17 | 2024 | 470 | 2.780 |
Why?
|
| Visual Pathways | 55 | 2018 | 150 | 2.670 |
Why?
|
| Nerve Net | 14 | 2021 | 404 | 2.650 |
Why?
|
| Quinolines | 9 | 2024 | 97 | 2.250 |
Why?
|
| Neural Inhibition | 18 | 2015 | 101 | 2.180 |
Why?
|
| Drug Overdose | 6 | 2025 | 104 | 2.140 |
Why?
|
| Phenylurea Compounds | 10 | 2024 | 112 | 2.010 |
Why?
|
| Tobacco Use | 7 | 2025 | 36 | 1.970 |
Why?
|
| Brain Mapping | 28 | 2017 | 570 | 1.950 |
Why?
|
| Electronic Nicotine Delivery Systems | 6 | 2025 | 91 | 1.890 |
Why?
|
| Tobacco Use Disorder | 7 | 2023 | 130 | 1.890 |
Why?
|
| Animals | 181 | 2021 | 29045 | 1.850 |
Why?
|
| HIV Infections | 16 | 2025 | 1024 | 1.850 |
Why?
|
| Mice, Inbred BALB C | 27 | 2015 | 1113 | 1.840 |
Why?
|
| Axons | 27 | 2011 | 182 | 1.840 |
Why?
|
| Mental Disorders | 6 | 2020 | 490 | 1.770 |
Why?
|
| Synaptic Transmission | 19 | 2014 | 229 | 1.690 |
Why?
|
| Counseling | 10 | 2025 | 191 | 1.650 |
Why?
|
| Tobacco Products | 4 | 2025 | 76 | 1.650 |
Why?
|
| In Vitro Techniques | 27 | 2017 | 945 | 1.490 |
Why?
|
| Photic Stimulation | 29 | 2015 | 525 | 1.390 |
Why?
|
| Interneurons | 15 | 2015 | 103 | 1.370 |
Why?
|
| Patch-Clamp Techniques | 22 | 2019 | 383 | 1.370 |
Why?
|
| Excitatory Postsynaptic Potentials | 15 | 2013 | 87 | 1.360 |
Why?
|
| Pharmaceutical Preparations | 3 | 2021 | 109 | 1.340 |
Why?
|
| Telephone | 5 | 2023 | 43 | 1.330 |
Why?
|
| Electric Stimulation | 33 | 2019 | 341 | 1.320 |
Why?
|
| Mentoring | 2 | 2022 | 48 | 1.310 |
Why?
|
| Auditory Pathways | 5 | 2012 | 35 | 1.280 |
Why?
|
| Glutamic Acid | 12 | 2016 | 136 | 1.260 |
Why?
|
| Telemedicine | 5 | 2025 | 256 | 1.260 |
Why?
|
| Retina | 29 | 2013 | 221 | 1.240 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2025 | 210 | 1.240 |
Why?
|
| Rural Population | 4 | 2021 | 196 | 1.230 |
Why?
|
| Drug Users | 2 | 2021 | 33 | 1.210 |
Why?
|
| Action Potentials | 28 | 2015 | 612 | 1.200 |
Why?
|
| Mice | 36 | 2020 | 12762 | 1.170 |
Why?
|
| Efferent Pathways | 6 | 2018 | 22 | 1.160 |
Why?
|
| Humans | 129 | 2025 | 98799 | 1.140 |
Why?
|
| Smokers | 4 | 2022 | 64 | 1.100 |
Why?
|
| Tobacco Smoking | 2 | 2019 | 33 | 1.090 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 2386 | 1.080 |
Why?
|
| Sex Workers | 4 | 2024 | 15 | 1.080 |
Why?
|
| United States Department of Veterans Affairs | 15 | 2025 | 50 | 1.070 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 166 | 1.030 |
Why?
|
| Male | 75 | 2025 | 47475 | 1.010 |
Why?
|
| Vaping | 2 | 2025 | 57 | 1.010 |
Why?
|
| Female | 76 | 2025 | 51997 | 0.980 |
Why?
|
| Health Services Accessibility | 6 | 2025 | 548 | 0.980 |
Why?
|
| Adenocarcinoma, Follicular | 3 | 2017 | 60 | 0.970 |
Why?
|
| Anti-HIV Agents | 5 | 2025 | 215 | 0.950 |
Why?
|
| Brain Stem | 12 | 2002 | 167 | 0.930 |
Why?
|
| Tobacco Use Cessation | 3 | 2020 | 15 | 0.910 |
Why?
|
| Vision, Ocular | 20 | 2005 | 73 | 0.870 |
Why?
|
| Afferent Pathways | 11 | 2013 | 61 | 0.860 |
Why?
|
| Adult | 49 | 2025 | 29698 | 0.860 |
Why?
|
| GABAergic Neurons | 2 | 2015 | 21 | 0.840 |
Why?
|
| Iodine Radioisotopes | 7 | 2024 | 145 | 0.820 |
Why?
|
| Mental Health Services | 3 | 2025 | 98 | 0.810 |
Why?
|
| Opioid-Related Disorders | 4 | 2025 | 258 | 0.810 |
Why?
|
| Xylazine | 1 | 2023 | 1 | 0.810 |
Why?
|
| Substance-Related Disorders | 8 | 2025 | 470 | 0.810 |
Why?
|
| Reagent Strips | 1 | 2023 | 5 | 0.810 |
Why?
|
| Limit of Detection | 1 | 2023 | 22 | 0.810 |
Why?
|
| Cross Reactions | 1 | 2023 | 116 | 0.790 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2024 | 642 | 0.770 |
Why?
|
| Behavior | 2 | 2021 | 86 | 0.760 |
Why?
|
| Visual Perception | 25 | 2003 | 342 | 0.760 |
Why?
|
| Qualitative Research | 7 | 2023 | 424 | 0.750 |
Why?
|
| United States | 34 | 2025 | 8387 | 0.750 |
Why?
|
| Smoking | 10 | 2024 | 676 | 0.750 |
Why?
|
| Ventral Thalamic Nuclei | 2 | 2015 | 6 | 0.750 |
Why?
|
| Middle Aged | 49 | 2025 | 29642 | 0.730 |
Why?
|
| Presynaptic Terminals | 5 | 2018 | 42 | 0.730 |
Why?
|
| Feedback, Physiological | 3 | 2013 | 71 | 0.720 |
Why?
|
| Delay Discounting | 1 | 2022 | 10 | 0.710 |
Why?
|
| Dendrites | 17 | 2010 | 101 | 0.710 |
Why?
|
| Sensory Deprivation | 23 | 2001 | 32 | 0.690 |
Why?
|
| Prostatic Neoplasms | 6 | 2025 | 1846 | 0.690 |
Why?
|
| West Virginia | 5 | 2021 | 10 | 0.670 |
Why?
|
| Naloxone | 3 | 2025 | 81 | 0.670 |
Why?
|
| Cognition | 3 | 2019 | 672 | 0.660 |
Why?
|
| Flavoproteins | 5 | 2011 | 24 | 0.650 |
Why?
|
| Water Pipe Smoking | 1 | 2020 | 5 | 0.650 |
Why?
|
| Aged | 37 | 2025 | 21986 | 0.630 |
Why?
|
| Neurosciences | 2 | 2018 | 52 | 0.620 |
Why?
|
| Electrophysiology | 26 | 2008 | 385 | 0.590 |
Why?
|
| Surveys and Questionnaires | 6 | 2025 | 3058 | 0.570 |
Why?
|
| Mesencephalon | 4 | 2010 | 68 | 0.570 |
Why?
|
| Anesthetics, Intravenous | 1 | 2019 | 45 | 0.570 |
Why?
|
| Joint Instability | 3 | 2025 | 105 | 0.560 |
Why?
|
| Animals, Newborn | 12 | 2015 | 528 | 0.560 |
Why?
|
| Neoplasms | 6 | 2025 | 3382 | 0.560 |
Why?
|
| Calcium | 13 | 2009 | 1205 | 0.560 |
Why?
|
| Microscopy, Fluorescence | 5 | 2011 | 435 | 0.560 |
Why?
|
| Medication Adherence | 2 | 2019 | 130 | 0.560 |
Why?
|
| Sensorimotor Cortex | 1 | 2018 | 16 | 0.550 |
Why?
|
| Models, Neurological | 10 | 2013 | 416 | 0.550 |
Why?
|
| Executive Function | 1 | 2019 | 116 | 0.550 |
Why?
|
| Young Adult | 20 | 2025 | 7598 | 0.540 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 25 | 0.530 |
Why?
|
| Excitatory Amino Acid Antagonists | 8 | 2012 | 78 | 0.530 |
Why?
|
| Attention | 2 | 2021 | 435 | 0.530 |
Why?
|
| Attitude of Health Personnel | 2 | 2023 | 688 | 0.510 |
Why?
|
| Lasers | 4 | 2011 | 105 | 0.510 |
Why?
|
| Hotlines | 1 | 2017 | 4 | 0.510 |
Why?
|
| Macaca mulatta | 6 | 2003 | 469 | 0.510 |
Why?
|
| Perception | 1 | 2018 | 190 | 0.510 |
Why?
|
| Central Nervous System Stimulants | 2 | 2025 | 246 | 0.510 |
Why?
|
| Inhibitory Postsynaptic Potentials | 3 | 2015 | 20 | 0.500 |
Why?
|
| Public Health | 1 | 2018 | 163 | 0.500 |
Why?
|
| Cartilage, Articular | 3 | 2023 | 86 | 0.500 |
Why?
|
| Synaptic Potentials | 3 | 2011 | 16 | 0.500 |
Why?
|
| Guideline Adherence | 4 | 2025 | 251 | 0.500 |
Why?
|
| Superior Colliculi | 9 | 2009 | 28 | 0.490 |
Why?
|
| Proteinuria | 1 | 2017 | 72 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 315 | 0.490 |
Why?
|
| Prosencephalon | 3 | 2013 | 70 | 0.490 |
Why?
|
| Health Policy | 1 | 2018 | 218 | 0.480 |
Why?
|
| Motor Cortex | 2 | 2018 | 214 | 0.480 |
Why?
|
| Exanthema | 1 | 2017 | 43 | 0.480 |
Why?
|
| GABA Antagonists | 7 | 2011 | 26 | 0.480 |
Why?
|
| Intralaminar Thalamic Nuclei | 3 | 2005 | 11 | 0.470 |
Why?
|
| Cycloleucine | 5 | 2003 | 10 | 0.470 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2015 | 48 | 0.470 |
Why?
|
| Behavior, Animal | 4 | 2021 | 399 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2025 | 669 | 0.460 |
Why?
|
| Diarrhea | 1 | 2017 | 180 | 0.460 |
Why?
|
| Fatigue | 1 | 2017 | 187 | 0.460 |
Why?
|
| Smoking Prevention | 1 | 2015 | 47 | 0.460 |
Why?
|
| gamma-Aminobutyric Acid | 9 | 2007 | 85 | 0.450 |
Why?
|
| Membrane Potentials | 15 | 2009 | 410 | 0.450 |
Why?
|
| Cross-Sectional Studies | 9 | 2025 | 2077 | 0.440 |
Why?
|
| Physicians | 2 | 2021 | 687 | 0.430 |
Why?
|
| Thyroid Gland | 2 | 2018 | 297 | 0.420 |
Why?
|
| Nerve Endings | 9 | 2010 | 15 | 0.420 |
Why?
|
| Thyroidectomy | 1 | 2015 | 181 | 0.420 |
Why?
|
| Patellar Dislocation | 2 | 2025 | 15 | 0.410 |
Why?
|
| Diagnostic Imaging | 4 | 2021 | 468 | 0.410 |
Why?
|
| Brain | 4 | 2021 | 2448 | 0.410 |
Why?
|
| Calcium Channels | 5 | 2005 | 180 | 0.410 |
Why?
|
| Mental Health | 5 | 2023 | 222 | 0.410 |
Why?
|
| Adenocarcinoma | 4 | 2024 | 1215 | 0.400 |
Why?
|
| Connectome | 1 | 2015 | 96 | 0.400 |
Why?
|
| Patellofemoral Joint | 2 | 2023 | 21 | 0.390 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 483 | 0.390 |
Why?
|
| Retinal Ganglion Cells | 7 | 1995 | 73 | 0.380 |
Why?
|
| Biological Evolution | 1 | 2021 | 1080 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 331 | 0.380 |
Why?
|
| Adolescent | 13 | 2025 | 10168 | 0.370 |
Why?
|
| Motivation | 5 | 2025 | 344 | 0.370 |
Why?
|
| Age Factors | 8 | 2024 | 1976 | 0.370 |
Why?
|
| Behavior Therapy | 2 | 2025 | 100 | 0.360 |
Why?
|
| Harm Reduction | 2 | 2025 | 37 | 0.350 |
Why?
|
| Excitatory Amino Acid Agonists | 4 | 2013 | 43 | 0.350 |
Why?
|
| Marijuana Abuse | 2 | 2022 | 32 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2020 | 9806 | 0.330 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 1196 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 995 | 0.320 |
Why?
|
| Rats | 11 | 2009 | 4079 | 0.320 |
Why?
|
| Neuronal Plasticity | 4 | 2014 | 200 | 0.320 |
Why?
|
| Feedback | 3 | 2021 | 132 | 0.320 |
Why?
|
| Needle-Exchange Programs | 2 | 2021 | 22 | 0.320 |
Why?
|
| Microscopy, Electron | 13 | 2004 | 435 | 0.310 |
Why?
|
| Appalachian Region | 2 | 2021 | 6 | 0.310 |
Why?
|
| Visual Fields | 24 | 1995 | 97 | 0.310 |
Why?
|
| Pulvinar | 3 | 2005 | 5 | 0.310 |
Why?
|
| Condoms | 3 | 2019 | 41 | 0.310 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2021 | 17 | 0.310 |
Why?
|
| Biomarkers, Tumor | 4 | 2017 | 1786 | 0.310 |
Why?
|
| Cholinergic Fibers | 1 | 2010 | 23 | 0.310 |
Why?
|
| Orthopedic Procedures | 2 | 2023 | 163 | 0.300 |
Why?
|
| Poverty | 2 | 2022 | 216 | 0.300 |
Why?
|
| Receptors, Muscarinic | 2 | 2007 | 42 | 0.300 |
Why?
|
| Veterans Health | 5 | 2023 | 23 | 0.300 |
Why?
|
| Time Factors | 12 | 2019 | 5586 | 0.300 |
Why?
|
| Referral and Consultation | 3 | 2022 | 419 | 0.300 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2009 | 19 | 0.300 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2009 | 3 | 0.300 |
Why?
|
| Sex Factors | 4 | 2024 | 1144 | 0.300 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 69 | 0.300 |
Why?
|
| Tetrodotoxin | 6 | 2007 | 51 | 0.300 |
Why?
|
| Electrophysiological Phenomena | 3 | 2018 | 51 | 0.290 |
Why?
|
| Self Report | 4 | 2019 | 357 | 0.290 |
Why?
|
| Binge Drinking | 2 | 2020 | 19 | 0.290 |
Why?
|
| Alcohol Drinking | 2 | 2025 | 302 | 0.290 |
Why?
|
| Sensory Receptor Cells | 1 | 2009 | 40 | 0.280 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 675 | 0.280 |
Why?
|
| Biotin | 2 | 2008 | 45 | 0.280 |
Why?
|
| Immunohistochemistry | 9 | 2012 | 1818 | 0.280 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 7461 | 0.280 |
Why?
|
| Neurotransmitter Agents | 2 | 2017 | 102 | 0.270 |
Why?
|
| Lateral Thalamic Nuclei | 2 | 2005 | 4 | 0.270 |
Why?
|
| Double-Blind Method | 6 | 2018 | 1793 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2009 | 1256 | 0.270 |
Why?
|
| Sexual Behavior | 4 | 2023 | 343 | 0.270 |
Why?
|
| Anilides | 3 | 2024 | 50 | 0.270 |
Why?
|
| Social Stigma | 2 | 2019 | 98 | 0.270 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 1608 | 0.270 |
Why?
|
| Electronic Health Records | 4 | 2022 | 456 | 0.270 |
Why?
|
| Transgender Persons | 2 | 2020 | 121 | 0.260 |
Why?
|
| Serotonin | 2 | 2008 | 211 | 0.260 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 186 | 0.260 |
Why?
|
| Substance Abuse Detection | 2 | 2025 | 14 | 0.260 |
Why?
|
| Reticular Formation | 2 | 2006 | 17 | 0.260 |
Why?
|
| Sensation | 1 | 2007 | 49 | 0.250 |
Why?
|
| Prevalence | 7 | 2019 | 1396 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2025 | 426 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2021 | 608 | 0.240 |
Why?
|
| Reaction Time | 9 | 2001 | 323 | 0.240 |
Why?
|
| Olfactory Pathways | 1 | 2006 | 28 | 0.240 |
Why?
|
| Optogenetics | 2 | 2018 | 48 | 0.240 |
Why?
|
| Pyridines | 3 | 2024 | 317 | 0.240 |
Why?
|
| New York City | 3 | 2020 | 75 | 0.230 |
Why?
|
| Neurons, Afferent | 6 | 2010 | 72 | 0.230 |
Why?
|
| United Arab Emirates | 1 | 2025 | 2 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 170 | 0.220 |
Why?
|
| Underage Drinking | 1 | 2025 | 4 | 0.220 |
Why?
|
| Risk Factors | 10 | 2025 | 6295 | 0.220 |
Why?
|
| Patella | 1 | 2025 | 31 | 0.220 |
Why?
|
| Functional Laterality | 12 | 1988 | 199 | 0.220 |
Why?
|
| Health Equity | 2 | 2024 | 117 | 0.210 |
Why?
|
| Pyridones | 1 | 2025 | 74 | 0.210 |
Why?
|
| Methacholine Chloride | 3 | 2010 | 61 | 0.210 |
Why?
|
| Narcotic Antagonists | 3 | 2025 | 181 | 0.210 |
Why?
|
| Schizophrenia | 3 | 2018 | 560 | 0.210 |
Why?
|
| Colorectal Neoplasms | 2 | 2025 | 1120 | 0.210 |
Why?
|
| Saccades | 2 | 2003 | 79 | 0.210 |
Why?
|
| Research Design | 2 | 2018 | 652 | 0.210 |
Why?
|
| Orientation | 8 | 2000 | 109 | 0.210 |
Why?
|
| Evoked Potentials | 12 | 2002 | 191 | 0.200 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2023 | 44 | 0.200 |
Why?
|
| Anxiety | 2 | 2025 | 376 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 2087 | 0.200 |
Why?
|
| Pandemics | 4 | 2024 | 923 | 0.200 |
Why?
|
| Computer Simulation | 4 | 2002 | 1152 | 0.200 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 285 | 0.200 |
Why?
|
| Ankle Injuries | 1 | 2023 | 37 | 0.200 |
Why?
|
| Platelet-Rich Plasma | 1 | 2023 | 14 | 0.200 |
Why?
|
| Horseradish Peroxidase | 12 | 1995 | 34 | 0.200 |
Why?
|
| Immunoassay | 1 | 2023 | 102 | 0.200 |
Why?
|
| Pyramidal Cells | 2 | 2018 | 85 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 108 | 0.190 |
Why?
|
| Pyridazines | 3 | 2009 | 24 | 0.190 |
Why?
|
| Models, Biological | 2 | 2008 | 1806 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2025 | 164 | 0.190 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 4049 | 0.190 |
Why?
|
| Health Behavior | 2 | 2022 | 203 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 1305 | 0.180 |
Why?
|
| Indomethacin | 2 | 2013 | 58 | 0.180 |
Why?
|
| Cohort Studies | 8 | 2025 | 3242 | 0.180 |
Why?
|
| Muscarinic Agonists | 3 | 2010 | 22 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 180 | 0.180 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2013 | 73 | 0.180 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2799 | 0.180 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 89 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 909 | 0.180 |
Why?
|
| Evoked Potentials, Visual | 5 | 1995 | 76 | 0.180 |
Why?
|
| Medical Marijuana | 1 | 2022 | 11 | 0.180 |
Why?
|
| Depression | 2 | 2025 | 625 | 0.180 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 925 | 0.180 |
Why?
|
| Optic Chiasm | 10 | 1991 | 17 | 0.170 |
Why?
|
| Persian Gulf Syndrome | 1 | 2021 | 6 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3628 | 0.170 |
Why?
|
| Interviews as Topic | 2 | 2025 | 390 | 0.170 |
Why?
|
| Biophysics | 3 | 2011 | 154 | 0.170 |
Why?
|
| Pancreatitis | 2 | 2013 | 108 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2025 | 400 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 521 | 0.170 |
Why?
|
| Acetylcholine | 3 | 2000 | 158 | 0.170 |
Why?
|
| Cannabis | 1 | 2022 | 41 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 59 | 0.170 |
Why?
|
| Syringes | 1 | 2021 | 15 | 0.170 |
Why?
|
| Urology | 1 | 2023 | 145 | 0.170 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 7 | 0.170 |
Why?
|
| Electroencephalography | 3 | 2003 | 801 | 0.170 |
Why?
|
| Mutation | 3 | 2019 | 4443 | 0.170 |
Why?
|
| Cartilage Diseases | 1 | 2021 | 13 | 0.170 |
Why?
|
| Focus Groups | 2 | 2019 | 215 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2023 | 122 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 558 | 0.170 |
Why?
|
| Evidence-Based Medicine | 3 | 2020 | 483 | 0.170 |
Why?
|
| Orthopedics | 1 | 2023 | 143 | 0.170 |
Why?
|
| Cocaine | 1 | 2022 | 85 | 0.160 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 264 | 0.160 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 546 | 0.160 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 25 | 0.160 |
Why?
|
| Erectile Dysfunction | 1 | 2021 | 81 | 0.160 |
Why?
|
| GABA-A Receptor Antagonists | 2 | 2013 | 14 | 0.160 |
Why?
|
| Smoking Water Pipes | 1 | 2020 | 2 | 0.160 |
Why?
|
| Culture | 1 | 2021 | 57 | 0.160 |
Why?
|
| Fluorescence | 2 | 2011 | 100 | 0.160 |
Why?
|
| Trust | 1 | 2021 | 107 | 0.160 |
Why?
|
| Reminder Systems | 1 | 2020 | 19 | 0.160 |
Why?
|
| Sexual Partners | 2 | 2019 | 107 | 0.160 |
Why?
|
| Orthopedic Surgeons | 1 | 2020 | 21 | 0.160 |
Why?
|
| Medical Order Entry Systems | 1 | 2020 | 29 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2020 | 32 | 0.160 |
Why?
|
| Knee Injuries | 1 | 2020 | 57 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 211 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2024 | 915 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 402 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 563 | 0.150 |
Why?
|
| Sports Medicine | 1 | 2020 | 62 | 0.150 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2019 | 3 | 0.150 |
Why?
|
| Injections | 3 | 2025 | 131 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 753 | 0.150 |
Why?
|
| Pregnancy | 3 | 2024 | 3286 | 0.150 |
Why?
|
| Receptors, AMPA | 3 | 2009 | 72 | 0.150 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 11 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1946 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2024 | 11104 | 0.150 |
Why?
|
| Needle Sharing | 1 | 2019 | 16 | 0.140 |
Why?
|
| Baltimore | 1 | 2019 | 42 | 0.140 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 179 | 0.140 |
Why?
|
| Social Environment | 1 | 2020 | 199 | 0.140 |
Why?
|
| Token Economy | 1 | 2018 | 1 | 0.140 |
Why?
|
| Safe Sex | 1 | 2019 | 24 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2021 | 110 | 0.140 |
Why?
|
| Heroin | 1 | 2019 | 15 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 1128 | 0.140 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 14 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2022 | 207 | 0.140 |
Why?
|
| Criminal Law | 1 | 2018 | 16 | 0.140 |
Why?
|
| Nitrites | 1 | 2018 | 34 | 0.140 |
Why?
|
| Mouth | 1 | 2018 | 53 | 0.140 |
Why?
|
| Thyroid Nodule | 2 | 2017 | 65 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2019 | 65 | 0.140 |
Why?
|
| Multimorbidity | 1 | 2018 | 6 | 0.140 |
Why?
|
| Fee-for-Service Plans | 1 | 2018 | 34 | 0.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2009 | 96 | 0.140 |
Why?
|
| Medicare | 2 | 2021 | 528 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2021 | 517 | 0.130 |
Why?
|
| Liraglutide | 1 | 2017 | 14 | 0.130 |
Why?
|
| Calcitonin | 1 | 2017 | 41 | 0.130 |
Why?
|
| ROC Curve | 2 | 2002 | 797 | 0.130 |
Why?
|
| Fentanyl | 1 | 2019 | 96 | 0.130 |
Why?
|
| Phosphinic Acids | 2 | 2009 | 4 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2022 | 408 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 649 | 0.130 |
Why?
|
| Patient Discharge | 2 | 2020 | 385 | 0.130 |
Why?
|
| Cholinergic Agents | 1 | 1997 | 18 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2019 | 111 | 0.130 |
Why?
|
| Knee Joint | 3 | 2023 | 181 | 0.130 |
Why?
|
| Data Collection | 1 | 2018 | 376 | 0.130 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 15 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 196 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 269 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 23 | 0.120 |
Why?
|
| Spouse Abuse | 1 | 2016 | 12 | 0.120 |
Why?
|
| Fluorescent Dyes | 2 | 2012 | 257 | 0.120 |
Why?
|
| Basal Ganglia | 1 | 2017 | 47 | 0.120 |
Why?
|
| Medical Informatics Applications | 1 | 2016 | 8 | 0.120 |
Why?
|
| Gender-Based Violence | 1 | 2016 | 1 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2018 | 323 | 0.120 |
Why?
|
| Prostate | 1 | 2020 | 434 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 84 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 89 | 0.120 |
Why?
|
| Dextrans | 2 | 2008 | 77 | 0.120 |
Why?
|
| Social Determinants of Health | 1 | 2018 | 149 | 0.120 |
Why?
|
| Reproductive Health | 1 | 2016 | 36 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 419 | 0.120 |
Why?
|
| Pain Management | 1 | 2018 | 198 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2017 | 226 | 0.120 |
Why?
|
| Hospitalization | 2 | 2020 | 993 | 0.120 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 78 | 0.120 |
Why?
|
| Space Perception | 6 | 1992 | 113 | 0.110 |
Why?
|
| Contraception | 1 | 2016 | 105 | 0.110 |
Why?
|
| Social Control, Informal | 1 | 2015 | 7 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 106 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 2026 | 0.110 |
Why?
|
| Cell Count | 3 | 2012 | 195 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 343 | 0.110 |
Why?
|
| Microelectrodes | 3 | 2004 | 88 | 0.110 |
Why?
|
| Quality of Life | 2 | 2021 | 1904 | 0.110 |
Why?
|
| Prognosis | 3 | 2024 | 4139 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 241 | 0.110 |
Why?
|
| Chicago | 3 | 2025 | 1520 | 0.110 |
Why?
|
| Algorithms | 4 | 2021 | 2005 | 0.110 |
Why?
|
| Endocrinology | 1 | 2016 | 51 | 0.110 |
Why?
|
| Alcoholism | 1 | 2017 | 201 | 0.110 |
Why?
|
| Consensus | 3 | 2024 | 308 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1422 | 0.110 |
Why?
|
| Human Rights Abuses | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2859 | 0.110 |
Why?
|
| Hospitals | 1 | 2017 | 351 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2017 | 269 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 416 | 0.100 |
Why?
|
| Indoles | 1 | 2016 | 340 | 0.100 |
Why?
|
| Age of Onset | 1 | 2015 | 369 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2017 | 742 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 1102 | 0.100 |
Why?
|
| Logistic Models | 4 | 2019 | 1276 | 0.100 |
Why?
|
| Rhodopsin | 1 | 2013 | 21 | 0.100 |
Why?
|
| Disease Progression | 2 | 2015 | 1621 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2016 | 352 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 691 | 0.100 |
Why?
|
| Patient Admission | 1 | 2014 | 124 | 0.100 |
Why?
|
| Infant | 1 | 2021 | 3368 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 457 | 0.100 |
Why?
|
| Glutamates | 2 | 2010 | 85 | 0.100 |
Why?
|
| Dominance, Cerebral | 5 | 1983 | 58 | 0.100 |
Why?
|
| Global Health | 1 | 2015 | 216 | 0.100 |
Why?
|
| Abortion, Induced | 1 | 2016 | 169 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 165 | 0.100 |
Why?
|
| Resorcinols | 1 | 2013 | 5 | 0.100 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 142 | 0.100 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2013 | 26 | 0.100 |
Why?
|
| Optic Nerve | 2 | 1988 | 35 | 0.100 |
Why?
|
| Analysis of Variance | 2 | 2019 | 890 | 0.090 |
Why?
|
| Recurrence | 3 | 2025 | 1274 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2023 | 183 | 0.090 |
Why?
|
| Glycine | 1 | 2013 | 97 | 0.090 |
Why?
|
| Microbiota | 1 | 2018 | 473 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2020 | 2604 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2013 | 341 | 0.090 |
Why?
|
| Axonal Transport | 4 | 1997 | 30 | 0.090 |
Why?
|
| Lysine | 3 | 2001 | 170 | 0.090 |
Why?
|
| Photolysis | 1 | 2012 | 13 | 0.090 |
Why?
|
| Parasympathetic Nervous System | 2 | 2007 | 34 | 0.090 |
Why?
|
| Transfection | 1 | 2013 | 884 | 0.090 |
Why?
|
| Incidence | 1 | 2017 | 1798 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 557 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 519 | 0.090 |
Why?
|
| Hypertension | 1 | 2018 | 791 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 26 | 0.090 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 2009 | 15 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 2474 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2013 | 179 | 0.090 |
Why?
|
| Sensory Thresholds | 4 | 2001 | 53 | 0.080 |
Why?
|
| Health Surveys | 2 | 2025 | 254 | 0.080 |
Why?
|
| Amblyopia | 2 | 1982 | 6 | 0.080 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1990 | 24 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1116 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2025 | 2017 | 0.080 |
Why?
|
| Perfusion | 1 | 2012 | 272 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1293 | 0.080 |
Why?
|
| Comorbidity | 3 | 2019 | 1037 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 199 | 0.080 |
Why?
|
| Receptors, GABA-B | 1 | 2009 | 8 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 255 | 0.080 |
Why?
|
| Receptors, GABA-A | 1 | 2009 | 38 | 0.080 |
Why?
|
| Calbindin 2 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Calbindins | 1 | 2009 | 16 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2009 | 51 | 0.070 |
Why?
|
| Electron-Transferring Flavoproteins | 1 | 2009 | 2 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2009 | 8 | 0.070 |
Why?
|
| Homeostasis | 1 | 2012 | 474 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 1133 | 0.070 |
Why?
|
| Models, Animal | 1 | 2010 | 282 | 0.070 |
Why?
|
| Stents | 1 | 2013 | 442 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2021 | 4837 | 0.070 |
Why?
|
| Obesity | 1 | 2016 | 1079 | 0.070 |
Why?
|
| Receptors, GABA | 1 | 2009 | 11 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1656 | 0.070 |
Why?
|
| Purines | 1 | 2009 | 97 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2009 | 89 | 0.070 |
Why?
|
| Anesthesia | 3 | 2000 | 177 | 0.070 |
Why?
|
| Staining and Labeling | 2 | 2008 | 161 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2000 | 124 | 0.070 |
Why?
|
| Dizocilpine Maleate | 1 | 2008 | 12 | 0.070 |
Why?
|
| Electron Transport Complex IV | 1 | 2008 | 48 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 193 | 0.070 |
Why?
|
| Hospitals, Veterans | 2 | 2019 | 24 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 197 | 0.070 |
Why?
|
| Ocular Physiological Phenomena | 3 | 1977 | 10 | 0.070 |
Why?
|
| Time Perception | 3 | 1982 | 23 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 901 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 869 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 122 | 0.060 |
Why?
|
| Zambia | 2 | 2019 | 11 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 195 | 0.060 |
Why?
|
| Thailand | 2 | 2019 | 69 | 0.060 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 28 | 0.060 |
Why?
|
| Brazil | 2 | 2019 | 93 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 137 | 0.060 |
Why?
|
| Macaca | 2 | 2005 | 83 | 0.060 |
Why?
|
| Auditory Perception | 1 | 2008 | 104 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2023 | 687 | 0.060 |
Why?
|
| Phytohemagglutinins | 3 | 1991 | 20 | 0.060 |
Why?
|
| Smell | 1 | 2006 | 123 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2006 | 146 | 0.060 |
Why?
|
| Diketopiperazines | 1 | 2025 | 11 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1007 | 0.060 |
Why?
|
| Wakefulness | 2 | 2003 | 128 | 0.060 |
Why?
|
| Rhode Island | 1 | 2025 | 11 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2025 | 125 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 240 | 0.050 |
Why?
|
| Cell Size | 1 | 2005 | 72 | 0.050 |
Why?
|
| Louisiana | 1 | 2024 | 20 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 312 | 0.050 |
Why?
|
| Macaca fascicularis | 2 | 2001 | 111 | 0.050 |
Why?
|
| Potassium | 2 | 2001 | 230 | 0.050 |
Why?
|
| Texas | 1 | 2024 | 137 | 0.050 |
Why?
|
| Learning | 2 | 2014 | 313 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2024 | 58 | 0.050 |
Why?
|
| Social Networking | 1 | 2025 | 96 | 0.050 |
Why?
|
| Fourier Analysis | 3 | 2009 | 124 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2025 | 677 | 0.050 |
Why?
|
| Ligaments, Articular | 1 | 2023 | 40 | 0.050 |
Why?
|
| Ankle Joint | 1 | 2023 | 45 | 0.050 |
Why?
|
| Censuses | 1 | 2023 | 12 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1949 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2025 | 356 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2024 | 44 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2023 | 215 | 0.050 |
Why?
|
| Urologists | 1 | 2023 | 39 | 0.050 |
Why?
|
| Differential Threshold | 2 | 2000 | 11 | 0.050 |
Why?
|
| Documentation | 1 | 2024 | 114 | 0.050 |
Why?
|
| Radiography | 1 | 2025 | 763 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 818 | 0.050 |
Why?
|
| Osteotomy | 1 | 2023 | 44 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 2057 | 0.050 |
Why?
|
| Administration, Rectal | 2 | 2013 | 13 | 0.050 |
Why?
|
| Motion Perception | 5 | 1991 | 104 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 77 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2024 | 159 | 0.050 |
Why?
|
| Tibia | 1 | 2023 | 86 | 0.050 |
Why?
|
| Neural Conduction | 5 | 1985 | 72 | 0.050 |
Why?
|
| Electrodes, Implanted | 1 | 2003 | 192 | 0.040 |
Why?
|
| Child | 2 | 2023 | 7771 | 0.040 |
Why?
|
| Vision Disorders | 1 | 1982 | 73 | 0.040 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.040 |
Why?
|
| Microinjections | 2 | 1995 | 67 | 0.040 |
Why?
|
| Pattern Recognition, Visual | 2 | 2000 | 159 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 246 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2002 | 244 | 0.040 |
Why?
|
| Cesium | 1 | 2001 | 16 | 0.040 |
Why?
|
| Aging | 2 | 2023 | 772 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2021 | 63 | 0.040 |
Why?
|
| Electrodes | 2 | 1991 | 90 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2000 | 10 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2022 | 330 | 0.040 |
Why?
|
| Cholinergic Agonists | 1 | 2000 | 11 | 0.040 |
Why?
|
| Nicotine | 1 | 2022 | 218 | 0.040 |
Why?
|
| Carbachol | 1 | 2000 | 34 | 0.040 |
Why?
|
| Pons | 1 | 2000 | 25 | 0.040 |
Why?
|
| Ferrets | 1 | 2000 | 50 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 244 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 252 | 0.040 |
Why?
|
| HIV | 1 | 2020 | 48 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2000 | 167 | 0.040 |
Why?
|
| Calcium Channels, T-Type | 1 | 2000 | 28 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2001 | 144 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3622 | 0.040 |
Why?
|
| Magnesium | 1 | 2000 | 175 | 0.040 |
Why?
|
| Nicotinic Agonists | 1 | 2000 | 74 | 0.040 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1997 | 25 | 0.040 |
Why?
|
| Vision, Monocular | 2 | 2001 | 15 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1102 | 0.040 |
Why?
|
| Asia, Western | 1 | 2019 | 3 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2023 | 1530 | 0.040 |
Why?
|
| Periodicity | 1 | 2000 | 115 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2000 | 94 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 214 | 0.040 |
Why?
|
| Varenicline | 1 | 2019 | 17 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 93 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 398 | 0.040 |
Why?
|
| Bupropion | 1 | 2019 | 24 | 0.040 |
Why?
|
| Athletic Injuries | 1 | 2020 | 113 | 0.040 |
Why?
|
| HIV Serosorting | 1 | 2018 | 4 | 0.040 |
Why?
|
| Haplorhini | 2 | 1976 | 77 | 0.040 |
Why?
|
| France | 1 | 2018 | 53 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 178 | 0.040 |
Why?
|
| Kinetics | 2 | 1996 | 1478 | 0.030 |
Why?
|
| Pain | 1 | 2021 | 417 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2019 | 42 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 61 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 183 | 0.030 |
Why?
|
| NADPH Dehydrogenase | 2 | 1994 | 11 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 210 | 0.030 |
Why?
|
| Reference Values | 3 | 1994 | 608 | 0.030 |
Why?
|
| Shrews | 1 | 1977 | 5 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 73 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2017 | 149 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1997 | 98 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 978 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2018 | 100 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 815 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 65 | 0.030 |
Why?
|
| Blindness | 1 | 1977 | 39 | 0.030 |
Why?
|
| Iontophoresis | 1 | 1996 | 4 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 728 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 371 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 610 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 290 | 0.030 |
Why?
|
| Public Sector | 1 | 2016 | 14 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 132 | 0.030 |
Why?
|
| Sex Offenses | 1 | 2016 | 26 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 527 | 0.030 |
Why?
|
| Private Sector | 1 | 2016 | 25 | 0.030 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 291 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1305 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 273 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 349 | 0.030 |
Why?
|
| Bangladesh | 1 | 2016 | 366 | 0.030 |
Why?
|
| Tupaiidae | 1 | 1975 | 1 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2018 | 413 | 0.030 |
Why?
|
| Strepsirhini | 1 | 1975 | 7 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 991 | 0.030 |
Why?
|
| Discrimination Learning | 3 | 1983 | 63 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 583 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 24 | 0.030 |
Why?
|
| Wheat Germ Agglutinins | 2 | 1993 | 15 | 0.030 |
Why?
|
| Adaptation, Physiological | 2 | 1994 | 352 | 0.030 |
Why?
|
| Electric Conductivity | 2 | 1987 | 142 | 0.030 |
Why?
|
| Niacinamide | 1 | 2014 | 105 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 519 | 0.030 |
Why?
|
| Human Rights | 1 | 2014 | 21 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 167 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 62 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 120 | 0.030 |
Why?
|
| Bicuculline | 1 | 1994 | 18 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 169 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1572 | 0.020 |
Why?
|
| Health Promotion | 1 | 2014 | 175 | 0.020 |
Why?
|
| Sphincter of Oddi Dysfunction | 1 | 2012 | 1 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1993 | 286 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1792 | 0.020 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1990 | 11 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 1990 | 45 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 1990 | 62 | 0.020 |
Why?
|
| Valine | 1 | 2009 | 48 | 0.020 |
Why?
|
| Eyelids | 2 | 1994 | 20 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2680 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 889 | 0.020 |
Why?
|
| Temporal Lobe | 2 | 1977 | 188 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1986 | 126 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1996 | 3642 | 0.010 |
Why?
|
| Dark Adaptation | 1 | 1984 | 12 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1994 | 122 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1987 | 681 | 0.010 |
Why?
|
| Ganglia | 2 | 1973 | 12 | 0.010 |
Why?
|
| Psychophysics | 1 | 1982 | 72 | 0.010 |
Why?
|
| Growth | 1 | 1982 | 42 | 0.010 |
Why?
|
| Sutures | 1 | 1982 | 60 | 0.010 |
Why?
|
| Photomicrography | 1 | 1981 | 7 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1981 | 429 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1982 | 517 | 0.010 |
Why?
|
| Form Perception | 1 | 1980 | 35 | 0.010 |
Why?
|
| Arousal | 1 | 2000 | 177 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 691 | 0.010 |
Why?
|
| Nictitating Membrane | 1 | 1977 | 1 | 0.010 |
Why?
|
| Pyramidal Tracts | 1 | 1977 | 16 | 0.010 |
Why?
|
| Cerebral Decortication | 1 | 1975 | 1 | 0.010 |
Why?
|
| Visual Field Tests | 1 | 1975 | 16 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 1974 | 49 | 0.010 |
Why?
|
| Dogs | 1 | 1975 | 642 | 0.010 |
Why?
|
| Environment | 1 | 1976 | 233 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1994 | 142 | 0.010 |
Why?
|
| Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 1 | 1993 | 3 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1993 | 41 | 0.010 |
Why?
|
| Macula Lutea | 1 | 1973 | 18 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 1973 | 79 | 0.010 |
Why?
|
| Depth Perception | 1 | 1971 | 18 | 0.010 |
Why?
|
| Mathematics | 1 | 1971 | 176 | 0.010 |
Why?
|
| Light | 1 | 1972 | 289 | 0.010 |
Why?
|
| Darkness | 1 | 1979 | 47 | 0.000 |
Why?
|